COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #110 of 257
8/5 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Singer et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218500 (Letter)
Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Source   PDF   Share   Tweet
Comparison of the percentage of SLE/RA patients on immunosuppressants that were taking HCQ, for COVID-19 diagnosis versus other infections or outpatient visits, finding a similar percentage in each case.
No mortality of severity information is provided to determine if HCQ treated patients fared better. No adjustment for concomitant medications or severity.

Singer et al., 8/5/2020, retrospective, database analysis, USA, North America, preprint, 3 authors.
risk of COVID-19 case, 9.0% higher, RR 1.09, p = 0.62, treatment 55 of 10700 (0.5%), control 104 of 22058 (0.5%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.